Insulin Delivery Devices Market - Snapshot

The global insulin delivery devices market is driven by a rise in the prevalence of diabetes and related major chronic diseases. The global market was valued at US$ 10,385.0 Mn in 2017 and is projected to reach US$ 21,783.3 Mn by 2026, expanding at a CAGR of 8.7% from 2018 to 2026. Increase in the number of chronic diseases related to diabetes such as cardiovascular diseases (increased threat of heart attacks and congestive heart failure), renal failure, hepatic disorders, immunodeficiency, loss of vision, brain and nervous system disorders, and impaired injury healing time are likely to drive the global insulin delivery devices market.

insulin delivery devices industry

Insulin delivery devices are used in the treatment of type 1 and type 2 diabetes. The devices have been categorized into four major segments: insulin syringe, insulin pens, insulin pumps, and others. Insulin delivery devices are often recommended when an individual is suffering from symptoms such as an increase in blood sugar levels or conditions such as dysfunctional pancreas. Thus, insulin delivery devices help patients maintain blood glucose levels in the normal range. Nowadays, physicians prefer insulin pens/pumps due to their several application and advantages. Insulin delivery devices are used in hospitals, specialty clinics, diabetes centers, etc.. The devices are designed with several properties such as safety, accuracy in dosing, and stability. Rise in demand for products and increase in awareness about insulin delivery devices are anticipated to propel the global insulin delivery devices market. Rise in the incidence of pediatric diabetes and geriatric diabetes disorders has resulted in a rise in demand for insulin delivery devices globally. According to the International Diabetes Federation, in 2016, 422 million people worldwide were living with diabetes. It is estimated that by 2040, more than 10% of the world’s adult population, or around 642 million people, will have diabetes.

The global insulin delivery devices market has been segmented based on product, distribution channel, and region. In terms of product, the global market can be classified into insulin syringes, insulin pens, insulin pumps, and others. In terms of product, the insulin pens segment accounted for a major share of the global market, in terms of revenue, in 2017. The segment is projected to expand at a significant growth rate during the forecast period due to the high adoption rate, rising popularity among consumers, and user-friendly design of insulin pens.

Based on distribution channel, the global insulin delivery devices market has been classified into hospital pharmacy, retail pharmacy, online sales, and diabetes clinics/centers. The hospital pharmacy segment dominated the global market in 2017, and the trend is likely to continue during the forecast period. This is attributed to an increase in demand for insulin delivery devices from diabetic patients during their hospital stay for different treatments including surgery, cardiovascular diseases, and others.

In terms of region, the global insulin delivery devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to gain market share by the end of 2026. The U.S. is a major country of the market in North America. Factors such as rise in the aging population, highly structured health care industry, and availability of well-defined reimbursement policies from public and private health insurance firms are fueling the insulin delivery devices market in U.S. The insulin delivery devices market in Asia Pacific is projected to expand at a rapid pace during the forecast period. China dominated the insulin delivery devices market in the region. The market in China is expected to expand at a high CAGR during the forecast period.

Major players operating in the global insulin delivery devices market include B. Braun Melsungen AG, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Medtronic plc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Biocon Ltd., Owen Mumford Ltd., Ypsomed Holding AG,

Cellnovo Group SA., Valeritas, Inc., Insulet Corporation, SOOIL Developments Co., Ltd, MannKind Corporation, and Tandem Diabetes Care, Inc. These companies are adopting the strategy of acquisition and collaboration in order to strengthen their position in the global market.

Insulin Delivery Devices Market - Overview

This report studies the current as well as future prospects of the global insulin delivery devices market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of insulin delivery devices and new players planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing information about various segments considered in the scope of the study. This section also provides the information and data analysis of the global insulin delivery devices market with respect to the leading segments based on product type, distribution channel, and region.

Based on product type, the global insulin delivery devices market has been categorized into insulin syringes, insulin pens, insulin pumps, and others. Each of the segments has been extensively analyzed based on market-related factors such as incidence and prevalence of diabetes and major chronic diseases. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global insulin delivery devices market and are likely to influence it in the near future. Market attractiveness analysis has been provided in the overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among market players has been evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and expand their shares in the global insulin delivery devices market.

In terms of geography, the global insulin delivery devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The report also provides the market size and forecast for major countries/sub-regions in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, Porter’s Five Forces analysis, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global insulin delivery devices market.

Key players operating in the global insulin delivery devices market include B. Braun Melsungen AG, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Medtronic plc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Biocon Ltd., Owen Mumford Ltd., Ypsomed Holding AG, Cellnovo Group SA., Valeritas, Inc., Insulet Corporation, SOOIL Developments Co., Ltd, MannKind Corporation, and Tandem Diabetes Care, Inc.

 

 

The global insulin delivery devices market has been segmented as follows: 

Global Insulin Delivery Devices Market, by Product Type

  • Insulin Syringe
  • Insulin Pens
  • Insulin Pumps
  • Others (Insulin Patches & Needle-free Injection Jet)

Global Insulin Delivery Devices Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Sales
  • Diabetes Clinics/Centers

Global Insulin Delivery Devices Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
.